These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 23290951)

  • 21. Oral antiplatelet agents in ACS: from pharmacology to clinical differences.
    Agewall S; Badimon L; Drouet L; Eschenhagen T; Husted S; Simon T; Steg G
    Fundam Clin Pharmacol; 2011 Oct; 25(5):564-71. PubMed ID: 21077944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Prog Cardiovasc Dis; 2015; 58(3):267-77. PubMed ID: 26277706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prasugrel versus clopidogrel: new management strategies for acute coronary syndrome.
    Schnapf AJ
    J Cardiovasc Nurs; 2013; 28(5):483-94. PubMed ID: 22990232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
    Coleman CI; Limone BL
    Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
    Anderson SD; Shah NK; Yim J; Epstein BJ
    Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis.
    Selhorst G; Schmidtler F; Ott A; Hitzke E; Tomelden J; Antoni D; Hoffmann E; Rieber J
    Platelets; 2019; 30(3):341-347. PubMed ID: 29521570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention.
    Faxon DP
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):181-97. PubMed ID: 21618679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ticagrelor: a novel reversible oral antiplatelet agent.
    Nawarskas JJ; Clark SM
    Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options.
    Morel O; Muller C; Jesel L; Moulin B; Hannedouche T
    Nephrol Dial Transplant; 2013 Aug; 28(8):1994-2002. PubMed ID: 23476040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cangrelor: a novel P2Y12 receptor antagonist.
    Norgard NB
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1219-30. PubMed ID: 19604122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic role of platelet reactivity in patients with acute coronary syndromes.
    Cavallari I; Nusca A; Ricottini E; Di Sciascio G
    Cardiol Rev; 2014; 22(6):313-8. PubMed ID: 25050977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
    Rollini F; Tello-Montoliu A; Angiolillo DJ
    Platelets; 2012; 23(7):537-51. PubMed ID: 22812566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered.
    Cohen MV; Downey JM
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):179-90. PubMed ID: 24298192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions.
    Becker RC; Gibson CM; Jennings LK; Morrow DA
    Am J Cardiol; 2010 Oct; 106(8):S2-3. PubMed ID: 20920638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests.
    Valgimigli M
    J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S8-S15. PubMed ID: 24378839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.